CRF Inc. (CRF), a global provider of electronic Patient Reported Outcomes (ePRO) for the Life Science Industry, will be providing delegates at the Society for Clinical Data Management (SCDM) Annual Conference with 250 Windows Mobile hand-held PDAs.
Dallas, TX – September 22, 2008
: CRF Inc. (CRF), a leading global provider of electronic Patient Reported Outcomes (ePRO) for the Life Science Industry, will be providing delegates at the Society for Clinical Data Management (SCDM) Annual Conference with 250 Windows Mobile hand-held PDAs. For the first time, CRF’s electronic diaries (eDiaries) will be used by conference attendees to complete event evaluation surveys at the end of each session.
The conference features a number of sessions with presentations from industry leaders. The evaluation survey will focus on getting immediate feedback from delegates regarding the session content, setup, and speaker’s effectiveness. This research initiative will showcase the ease and speed at which data can be collected and submitted using electronic methods, thus demonstrating how the ePRO system is revolutionizing the clinical trial industry. The electronic surveys are modeled on the eDiaries used in clinical trials, are simple to use and have large, easily accessible buttons to allow fingertip entry.
Kim Breitbach, Executive Director of the SCDM, confirmed: “Gathering trend data is vital for us in getting instant feedback from our delegates. Paper surveys meant that a significant amount of time was spent in deciphering the questionnaires and collating the results. Thanks to CRF’s technology, we will save time and effort and we hope to get high compliance and valuable data from the initiative.”
Pamela McNamara, Chief Executive Officer of CRF, commented: “The fact that SCDM will be using our eDiaries for market research purposes illustrates that our technology is extremely flexible and can be adapted to fit many needs. Clinical Data Managers attending this year’s conference will have first-hand experience of how easy eDiaries are to use - an important attribute which impacts compliance levels in clinical research studies.”
CRF will be exhibiting at this year’s SCDM Conference at booth number 216.
About CRF Inc.
CRF Inc. (“CRF”) is a leading global provider of electronic Patient Reported Outcomes (“ePRO”) and wireless data collection solutions for the Life Science Industry. Through innovative technology and a thorough understanding of drug development and mobile computing, CRF is driving the change to safer and more efficient, paper-free clinical trials. CRF's technology has been used by more than 180,000 patients across 59 countries in 60 languages for 45 indications. The company has demonstrated one of the industry's highest patient compliance rates - an average 90% compliance through Phase I, II, III and IV clinical trials.
CRF's award-winning product, the TrialMax® suite, is a flexible and configurable ePRO technology that provides real-time patient monitoring, outstanding data accuracy and increased safety through compliance. The TrialMax application’s unique features enable clinical trial sponsors to rapidly collect valuable data and conduct complex clinical trials with greater flexibility than other ePRO solutions. CRF's experience, combined with its dedication to achieving the highest quality and most responsive customer service, has made the company one of the life-science industry's most trusted partners.
For more information, please visit www.crfhealth.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.